XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.4
SHARE-BASED PAYMENT (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity Plan
The grant date fair value of the stock options was determined using the Black Scholes model with the following assumptions:
 
Year Ended December 31, 2022
Exercise price
$2.42-$5.69
Expected terms (years)
6.00
Volatility
56.16%-57.84%
Risk-free interest rate
2.79%-3.02%
Expected dividend yields0.00 %
Weighted average fair value of options granted
$1.33-$3.19
During the year ended December 31, 2021, the modification date fair value of the stock options was determined using the Binomial-Lattice Model with the following assumptions:
 After
modification
Exercise price
$4.37-$6.28
Expected terms (years)
4.5-9.4
Volatility
47.6%-53.1%
Risk-free interest rate
1.26%-1.87%
Expected dividend yield
0.00%
Weighted average fair value of options modified
$4.70-$5.36
At the CRSU Modification date, the Company used the Monte Carlo valuation model in determining the fair value of the CRSUs with assumptions as follows:

Modification Date
Expected term (years)0.07~2.07
Volatility50.93 %~73.89%
Risk-free interest rate1.15 %~3.05%
Expected dividend yields0.00%
The following assumptions were used for the respective periods below to calculate the fair value of common shares to be issued under TSR awards on the date of grant using the Monte Carlo pricing model:
Year Ended December 31, 2021
Year Ended December 31, 2022
Expected term (years)
2.18-2.35
2.68
Volatility
63.06%-64.31%
59.50 %
Risk-free interest rate
0.31%-0.55%
2.72 %
Expected dividend yields0.00 %0.00 %
Schedule of Effective Time Fair Value of the Stock Options was Determined Using the BLM
Share options activity for the years ended December 31, 2022 was as follows:
Share options lifeNumber of Shares Weighted Average Exercise
Price (US$)
Weighted Average Grant Date
Fair Value (US$)
Weighted Average Remaining
Contractual
Outstanding as of January 1, 202233,503,657 6.19 4.95 7.9
Granted2,900,000 4.81 2.69  
Forfeited(312,586)6.28 4.87  
Outstanding as of December 31, 2022
36,091,071 6.08 4.80 6.8
Expected to vest and exercisable as of December 31, 2022
36,091,071 6.08 4.80 6.8
Exercisable as of December 31, 202211,875,830 6.20 5.00 7.0
Schedule Non-vested Shares Activity
CRSUs' activity for the years ended December 31, 2022 was as follows:
 Number on
Non-Vested
Shares
Weighted Average Grant
Date Fair Value
per Share (US$)
Outstanding as of January 1, 202223,027,399 8.74  1
Vested(9,582,930)4.37 
Outstanding as of December 31, 2022
13,444,469 2.38
The restricted stock units activity for the years ended December 31, 2022 was as follows:
 Number of
Non-Vested
Shares
Weighted
Average Grant
Date Fair Value
Per Share (US$)
Outstanding as of January 1, 2022671,441 9.08 
Grant1,239,854 4.93 
Vested(110,940)6.26 
Forfeited(577,518)5.30 
Outstanding as of December 31, 2022
1,222,837 6.92 
Schedule of Classification of Stock-based Compensation
The following summarizes the classification of share-based compensation:
Year Ended December 31,
202020212022
Cost of revenues$— $4,309 $7,712 
General and administrative expenses— 59,492 67,261 
Research and development expenses— 13,064 13,987 
Selling and marketing expenses— 6,029 6,745 
Construction in progress— 237 525 
Total$ $83,131 $96,230